The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Soo Hee KimSun Och Yoon

Abstract

Polycomb repressive complex 2 (PRC2; formed by EZH2, SUZ12, and EED protein subunits) and PRC1 (BMI1 protein) induce gene silencing through histone modification, primarily H3K27me3, and deregulation of PRC pathways leads to tumorigenesis. In the present study, activation of PRC2, H3K27me3, and BMI1 was investigated by immunohistochemistry in 175 cases of T and natural killer (NK) cell lymphoma. Activation of PRC proteins was analyzed according to c-MYC activation, Epstein-Barr virus (EBV) infection, CD30 activation, and survival. Among all T and NK cell lymphomas, high expression rates of 54.7 % for EZH2, 33.3 % for SUZ12, 85.7 % for EED, 40.5 % for H3K27me3, and 30.9 % for BMI1 were discovered. Activation of PRC2, H3K27me3, and BMI1 showed positive correlations (P < 0.05). Activation of c-MYC was associated with activation of SUZ12 and triple coactivation of all PRC2 protein subunits (EZH2(high)/SUZ12(high)/EED(high)) (P < 0.05). In EBV-positive tumors, activation of EZH2 and H3K27me3 showed greater association (P < 0.05). H3K27me3 and BMI1 showed a negative association in tumors expressing CD30 (P < 0.05). With respect to survival, BMI1 activation was independently associated with poor prognosis in T and NK cell lymphomas (P ...Continue Reading

References

Sep 29, 1999·Biochimica Et Biophysica Acta·D P Satijn, A P Otte
Oct 8, 2004·The Journal of Pathology·Margarita Sánchez-BeatoMiguel A Piris
Jul 14, 2006·Journal of Clinical Pathology·Joost C van GalenChris J L M Meijer
Aug 2, 2006·American Journal of Clinical Pathology·Ulrich F Vogel, Burkhard D Bueltmann
May 15, 2009·Histopathology·Lena MarquardElisabeth Ralfkiaer
Mar 30, 2010·Trends in Biochemical Sciences·Lluís Morey, Kristian Helin
Aug 19, 2010·Blood·Daniel Martin-PerezMargarita Sanchez-Beato
Feb 8, 2011·Cancer Investigation·Yan-Wei LinJing-Yuan Fang
May 31, 2011·Leukemia & Lymphoma·Yehuda E DeutschJoseph D Rosenblatt
Jan 6, 2012·The New England Journal of Medicine·Lucile CouronnéOlivier A Bernard
Jul 31, 2013·Epigenomics·Melanie R HasslerGerda Egger
Jul 31, 2013·Cellular and Molecular Life Sciences : CMLS·Leonidas BenetatosEleftheria Hatzimichael
Aug 21, 2013·Virchows Archiv : an International Journal of Pathology·Lamia Abd Al KaderTadashi Yoshino
Dec 18, 2013·Annals of Diagnostic Pathology·Amal Abd El hafez, Hend Ahmed El-Hadaad
Jul 21, 2014·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hirohito Yamaguchi, Mien-Chie Hung
Aug 3, 2014·Blood Cells, Molecules & Diseases·Niveen S SaudyEman M Abdul Salam
Oct 2, 2014·The FEBS Journal·Pedro VizánLuciano Di Croce
Feb 11, 2015·Breast Cancer Research and Treatment·Su-Hyeong Kim, Shivendra V Singh

❮ Previous
Next ❯

Citations

Mar 24, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Qiuhua ZhuFanyi Meng
May 27, 2017·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Juehua GaoYi-Hua Chen
Jul 3, 2019·Frontiers in Oncology·Mei Mei, Mingzhi Zhang
Mar 5, 2020·Therapeutic Advances in Medical Oncology·Can KüçükHua You
Jan 27, 2021·International Journal of Molecular Sciences·Sidney IrianaNeelam Sharma-Walia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Related Papers

Breast Cancer Research : BCR
Alexandra M PietersenMaarten van Lohuizen
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
Yingjun CuiYongtao Xiao
© 2021 Meta ULC. All rights reserved